folate receptor alpha (FRα)

December 6, 2019December 6, 2019

Sutro’s Investigational Antibody-Drug Conjugate Shows Promise in Advanced Ovarian Cancer Phase 1 Trial

News

STRO-002, an investigational antibody-drug conjugate being developed by Sutro Biopharma, is safe and shows promising efficacy in women with advanced ovarian, fallopian tube, or primary peritoneal cancer, early Phase 1 ... Read more

March 11, 2019

Mirvetuximab Soravtansine Fails to Delay Disease Progression in FRα-positive Ovarian Cancers, Trial Shows

News

Mirvetuximab soravtansine, an investigational antibody-drug conjugate targeting the folate receptor alpha (FRα) protein, was no better than chemotherapy at delaying disease progression or death in ovarian cancer patients included in ... Read more

October 17, 2018

Carrick Acquires Rights to CT900, Plans New Trial in Ovarian Cancer Patients

News

Carrick Therapeutics, a biopharmaceutical company, has acquired the rights to CT900 and plans to conduct a later-stage clinical trial to evaluate the safety and effectiveness of the investigational therapy in ... Read more

May 25, 2018May 25, 2018

Mirvetuximab Soravtansine Combo Therapies Show Promise for Ovarian Cancer, Clinical Trial Shows

News

Combinations of mirvetuximab soravtansine (IMGN853) with either Avastin (bevacizumab) or Paraplatin (carboplatin) are showing promise in certain ovarian cancer patients, particularly those who received multiple prior lines of therapy, the investigational therapy’s developer, ImmunoGen, recently announced. ... Read more